In 30 of 33 human systemic lupus erythematosus (SLE) sera and in 10 sera from MRL/I mice with spontaneous SLE, antibodies against heparan sulfate were detected. The anti-heparan sulfate titers showed a significant correlation with the anti-DNA antibody titers. By inhibition studies it was demonstrated that heparan sulfate could inhibit the binding of anti-DNA antibodies to DNA, whereas DNA could block the binding to heparan sulfate. That this reaction is due to crossreactivity of anti-DNA antibodies was further substantiated by the finding that two monoclonal anti-DNA antibodies also bound to heparan sulfate. Antibodies eluted from human and mouse kidneys with diffuse SLE glomerulonephritis showed a similar binding to DNA and heparan sulfate when these eluted antibodies were tested in vitro. Heparan sulfate is the major glycosaminoglycan constituent of the glomerular basement membrane. Our findings suggest that heparan sulfate might serve as a target antigen in vivo for crossreactive anti-DNA antibodies.
Introduction
Systemic lupus erythematosus (SLE)' is an autoimmune disease characterized by a great variety of apparently unrelated antibodies (1, 2) , thought to be a consequence of polyclonal B cell activation. Recent observations mainly obtained with monoclonal anti-DNA antibodies, however, indicate that the B cell activation in SLE might be more restricted than assumed until now (3) . It was shown that in addition to binding to DNA, human and murine monoclonal anti-DNA antibodies could also react with several crossreactive moieties like cardiolipin and other negatively charged phospholipids in micellar form (4, 5) . The moieties recognized in these crossreactive molecules are thought erythematosus.
to be the phosphodiester-linked phosphate groups, which show similarities to the sugar-phosphate backbone ofDNA. However, these phosphodiester-linked phosphate groups are not the only crossreactive moieties recognized, since monoclonal anti-DNA antibodies can also bind to Raji-cells (6) , B cells, T cells, erythrocytes (7) , and the cytoskeletal protein vimentin (8) . Moreover, we have recently reported that a monoclonal anti-DNA antibody can bind to hyaluronic acid and chondroitin sulfate (9) . These molecules do not contain phosphodiester-linked phosphate groups but have other repeating negatively charged units. Apparently also these structures can serve as crossreactive moieties for anti-DNA antibodies. The observed crossreactivity is not a unique property of monoclonal anti-DNA antibodies, because also with polyclonal anti-DNA antibodies crossreactions were demonstrated with Raji-cells (10) and negatively charged molecules like cardiolipin (1 1), hyaluronic acid, and chondroitin sulfate (9) . It seems that in SLE sera, a number of autoantibody specificities can be attributed to anti-DNA antibodies reacting with widely different molecules which all contain repeating negatively charged groups. We now present evidence that monoclonal and polyclonal anti-DNA antibodies can bind to heparan sulfate, the major glycosaminoglycan constituent of the glomerular basement membrane (12, 13) .
Methods
Anti-dsDNA positive sera. Sera containing anti-DNA antibodies were obtained from SLE patients and from 24-wk-old MRL/Mp/lpr/lpr (MRL/ 1) mice (originally obtained from The Jackson Laboratory, Bar Harbor, Maine). These MRL/I mice develop spontaneously an autoimmune disease very similar to human SLE, characterized by formation of anti-DNA antibodies, and diffuse proliferative glomerulonephritis ( 14) . After clotting for 3 h at room temperature and subsequent centrifugation for 5 min at 2,000 g, the sera were aliquoted and stored at -20°C. Inhibition studies. To demonstrate the specificity ofthe crossreactivity of anti-DNA antibodies with heparan sulfate, inhibition experiments were performed with DNA and heparan sulfate. SLE sera (n = 6) diluted to a concentration giving 75% of the maximal signal in the ELISA, were preincubated with an equal volume of 100 Ml of DNA or heparan sulfate at concentrations varying from 0.25 to 100 Mg/ml for 1 h at 37°C and subsequently for 1 h at 0°C. DNA used for these inhibition studies was commercially obtained calf thymus DNA (Sigma). To exclude the possibility that the observed inhibition is due to non-DNA nuclear constituents eventually present in this DNA preparation, we performed inhibition studies with DNA after digestion with DNAse I. The sera preincubated with heparan sulfate or DNA were tested in the ELISA with DNA or heparan sulfate as coated antigen.
Inhibition studies on anti-DNA binding were also performed with Cibacron Blue F3GA sepharose 6B (Pharmacia, Uppsala, Sweden), a sulphonated polyaromatic, polyanionic dye. SLE sera (n = 3) diluted to a concentration giving 75% of the maximal ELISA signal, were preincubated with an equal volume (100 ,l) ofPBS containing varying amounts (0.002-1.2 mM) ofCibacron Blue. The experiments were further carried out as described for the DNA and heparan sulfate inhibition studies.
To exclude that DNA, heparan sulfate or Cibacron Blue inhibited anti-DNA binding nonspecifically, they were tested for their ability to inhibit an unrelated antigen-antibody interaction, using BSA (Sigma) and rabbit anti-BSA (Dako, Copenhagen, Denmark). The anti-BSA antiserum was diluted to a concentration giving 75% ofthe maximal ELISA signal, with BSA as coated antigen. Diluted anti-BSA antiserum (100 M1) was incubated with 100 Ml solution containing the same range of concentrations of DNA, heparan sulfate, or Cibacron Blue as used in the DNA, heparan sulfate, or Cibacron Blue inhibition experiments of the SLE sera. The experiments were further carried out as described above, and the supernatants were tested in the ELISA with BSA as coated antigen.
ELISA with different salt concentrations. To test the influence of ionic strength on antibody binding, ELISAs with DNA or heparan sulfate were performed with different NaCl concentrations. After coating of the appropriate antigen under standard conditions, serum dilutions of three different SLE sera were applied in the presence of increasing NaCl concentrations (range, 0.15-3 M NaCl). After the first incubation step, the ELISA was further carried out according to the standard procedure. The NaCl concentrations used did not induce a dissociation of the coated antigens from the microtiter plates, since preincubation for 1 h at room temperature of the coated antigens with the used salt concentrations did not alter the subsequent binding of a known SLE serum.
Elution ofantibodiesfrom kidneys with diffuseSLE nephritis. Kidneys from 22-26-wk-old MRL/I mice, BALB/c mice, a part of a kidney from a patient with SLE glomerulonephritis, and a part of a normal human kidney were used for elution studies. These MRL/1 mice had all high anti-dsDNA antibody titers and diffuse proliferative glomerulonephritis with glomerular IgG deposits on immunofluorescence. Also the patient with a classic SLE and a biopsy-proven diffuse proliferative glomerulonephritis had high anti-dsDNA antibody titers. The kidneys used for control experiments showed no abnormalities on light microscopy and immunofluorescence. The kidney tissue was homogenized and washed extensively in 0.01 M PBS until no absorbance at 280 nm was found in the wash solution. The tissue homogenate was resuspended in 0.1 M sodium acetate buffer (pH 7.0) containing 10 mM calcium chloride and 5 mM magnesium chloride. To 15 g oftissue homogenate. 1 mg DNAse I and 10 U heparitinase were added. This mixture was incubated for 4 h at 37°C and 16 h at 4°C under constant stirring. The tissue homogenate was spun down in a SW34 rotor at 6,000 rpm for 15 min at 4°C. The pellet was resuspended in 30 ml 0.02 M citrate buffer pH 2.85, and under constant stirring incubated for 2 h at room temperature. After centrifugation (15 min, at 4°C in a SW34 rotor, 6,000 rpm) the elution procedure was repeated once. The supernatant was brought back immediately to pH 7 with Tris buffer. The precipitate formed during pH titration was removed by centrifugation. The eluate was dialyzed overnight against PBS, and subsequently concentrated with an Amicon YM 50 filter to a volume of 5 ml (Amicon Corp., Danvers, MA). The IgG content was determined nephelometrically. The control eluates ofthe BALB/c kidneys and the normal human kidney were concentrated to the same IgG concentrations as the MRL/l eluate and the human SLE eluate, respectively.
Additionally, an eluate of rat kidneys with experimentally induced Heymann's nephritis was used for control experiments. This eluate (IgG concentration 160 Mg/ml) was a generous gift from Dr. E. de Heer (Department of Nephrology, Leyden State University, Leyden, The Netherlands) and obtained as published before ( 18) .
Results
Reactivity ofhuman and murine SLE sera with heparan sulfate.
Of 33 human SLE sera (positive in the Farr assay, the Crithidia Binding ofAnti-DNA Antibodies to Heparan Sulfate 1825 luciliae test and DNA-ELISA), 30 showed a positive binding with heparan sulfate as tested in the ELISA. A representative serum is shown in Fig. 1 . As can be seen from Fig. 2 , we found a clear correlation (r = 0.73) between the anti-DNA titer and the anti-heparan sulfate titer in these 33 SLE sera. The mean anti-DNA titer ofthese sera was approximately three times higher (mean log 2 titer±SD; 8.7±1.9) than the mean anti-heparan sulfate titer (7.2±2.5). Of 33 SLE sera, 3 showed no binding activity for heparan sulfate although an evident binding to DNA was present. A significant correlation (r = 0.77) was also found between the anti-DNA titer and anti-heparan sulfate titer in 10 MRL/I mouse sera, which were all positive in the Farr assay and Crithidia luciliae test (data not shown). The binding activities of a serum pool from 40 healthy volunteers and of 8 sera from patients with rheumatoid arthritis were negative in the DNA as well as in the heparan sulfate ELISA. Also in sera from normal BALB/c mice (n = 40) anti-DNA as well as antiheparan sulfate activity was never detected. The observed binding of SLE sera to heparan sulfate can not be attributed to the higher IgG concentration of these sera since the mean IgG concentration of these SLE sera (22±9 mg/ml; range, 7.0-41 mg/ml) was only two to four times higher than the control sera (10 mg/ml) while the average binding to heparan sulfate of these SLE sera was -100 times higher than of the control sera. Furthermore, there was no correlation between the anti-heparan sulfate titer and the IgG concentration. Sera from patients with primary glomerulopathy [minimal lesions (n = 3), membranous glomerulopathy (n = 4), focal glomerulosclerosis (n = 2), and IgA nephropathy (n = 3)] and patients with glomerulopathy secondary to systemic diseases other than SLE (Wegener's granulomatosis (n = 12), Schonlein-Henoch purpura (n = 5), and periarteritis nodosa (n = 4)) were also tested for their reactivity in the DNA and heparan sulfate ELISA. None ofthese sera showed a positive binding to either of these antigens. To exclude any DNA contamination of the heparan sulfate preparation, 10 human SLE sera were tested with heparan sulfate pretreated with DNAse I. We observed no difference in binding activity of these sera with heparan sulfate whether it was pretreated with DNAse I or not. However, treatment of heparan sulfate with heparitinase abolished the binding activity of these SLE sera (n = 10) (data not shown).
Inhibition studies. To demonstrate that the binding to heparan sulfate was due to crossreactivity of anti-DNA antibodies, (Fig. 3 A) or heparan sulfate (Fig. 3 B) . Furthermore, it shows (Fig. 3 A) that digestion of heparan sulfate with heparitinase leads to a complete loss of the inhibitory effect of heparan sulfate.
The binding ofanti-DNA antibodies to DNA could not only be inhibited by heparan sulfate, but also by another, unrelated, highly polyanionic structure: Cibacron Blue. In the three SLE sera tested we found that Cibacron Blue exerted the same inhibitory effect on DNA binding as heparan sulfate. Fig. 4 DNA (e-) or heparan sulfate 
Discussion
This study shows that in 90% of human SLE sera (selected for the presence ofanti-dsDNA autoantibodies) and in all the murine SLE sera antibodies are present directed toward heparan sulfate. In these sera the anti-heparan sulfate titer was positively correlated with the anti-DNA titer (r = 0.73). Binding to heparan sulfate was not found with sera fiomn healthy volunteers, patients with rheumatoid arthritis, or patients with primary or secondary glomerulopathy due to systemic diseases other than SLE.
Inhibition studies revealed that heparan sulfate could block the binding to DNA and that DNA could inhibit the binding to heparan sulfate, indicating crossreactive recognition of heparan (20) .
Primarily based on studies with monoclonal antibodies (22, 23) anti-DNA antibodies can be divided in antibodies reactive with DNA nucleotides or nucleotide sequences and those reactive with the sugar phosphate backbone of DNA. The latter are thought to be responsible for crossreactive binding of anti-DNA antibodies to several molecules (3). There still exists, however, some controversy about the composition and characteristics of the crossreactive targets. Stollar, Schwartz, and co-workers (4, 5) have proposed that the crossreactive moieties are phosphodiester-linked phosphate groups. We propose, however, based on our previous experiments with hyaluronic acid and chondroitin sulfate (9), the reported reactivity of anti-DNA antibodies with Cibacron Blue (19, 20) and the present results with heparan sulfate and Cibacron Blue that molecules with repeating anionic sites also can serve as crossreactive antigenic targets for anti-DNA antibodies.
The crossreactivity of anti-DNA antibodies with the glycosaminoglycan heparan sulfate may play an important role in the immunopathogenesis of SLE glomerulonephritis. Heparan sulfate is the major glycosaminoglycan constituent ofthe glomerular basement membrane (GBM), and has a major role in the maintenance of the charge selective barrier of the GBM (24) . Furthermore, recent experiments have indicated that heparan sulfate may also have an important function in the integrity of the size-selective barrier of the GBM (25, 26) . Reduction or neutralization of heparan sulfate in the GBM leads to proteinuria in experimental animals (24, 27) . Clinically, a reduction of heparan sulfate-associated polyanionic sites has been held responsible for proteinuria in congenital nephrotic syndrome (28) . In addition to their function in glomerular permeability, there is now also evidence that anionic sites within the glomerulus may determine the intraglomerular handling of circulating antigens, antibodies, and immune complexes (29). Therefore binding of anti-DNA antibodies to the heparan sulfate associated polyanionic sites in the GBM might be an important event in SLE nephritis either by interference with physiological functions and/ or by triggering inflammatory reactions locally. This hypothesis implies that glomerulonephritis in SLE patients might occur by a direct binding of anti-DNA antibodies to heparan sulfate. Our finding that anti-DNA antibodies eluted from kidneys with diffuse SLE glomerulonephritis can bind to heparan sulfate in vitro supports this hypothesis. Studies are now in progress to see whether anti-heparan sulfate activity in the serum ofSLE patients is correlated with the presence of glomerulonephritis.
